Alpine Immune Sciences, Inc. Stock

Equities

ALPN

US02083G1004

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-05-17 EDT 5-day change 1st Jan Change
64.97 USD +0.02% Intraday chart for Alpine Immune Sciences, Inc. -.--% +240.87%
Sales 2022 30.06M 41.29M Sales 2023 58.88M 80.87M Capitalization 1.11B 1.52B
Net income 2022 -57M -78.29M Net income 2023 -32M -43.95M EV / Sales 2022 3.79 x
Net cash position 2022 223M 307M Net cash position 2023 317M 436M EV / Sales 2023 13.4 x
P/E ratio 2022
-4.25 x
P/E ratio 2023
-29.6 x
Employees 142
Yield 2022 *
-
Yield 2023
-
Free-Float 96.04%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Alpine Immune Sciences, Inc.

1 day+0.02%
1 month+0.03%
3 months+81.03%
6 months+244.12%
Current year+240.87%
More quotes
1 month
64.95
Extreme 64.95
65.00
Current year
17.32
Extreme 17.32
65.00
1 year
8.33
Extreme 8.33
65.00
3 years
4.82
Extreme 4.82
65.00
5 years
2.05
Extreme 2.05
65.00
10 years
2.05
Extreme 2.05
65.00
More quotes
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Related indices
More about the company